Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547709 | 0.86 | EP300 (0.36) | PIK3CDALDH1A1POLB | |
| SCHEMBL2544713 | 0.82 | METAP2 (0.44) | PIK3CDPDE10AADORA3ADORA2AADORA1 | |
| SCHEMBL2544705 | 0.82 | METAP2 (0.44) | PIK3CDPDE10AADORA3ADORA2AADORA1 | |
| SCHEMBL19254372 | 0.74 | METAP2 (0.42) | PIK3CD | |
| SCHEMBL12022034 | 0.73 | METAP2 (0.42) | PIK3CDADORA3ADORA2AADORA1 | |
| SCHEMBL12037948 | 0.73 | METAP2 (0.43) | PIK3CDPOLBADORA3ADORA2AADORA1 | |
| SCHEMBL20450252 | 0.72 | METAP2 (0.43) | PIK3CDADORA3ADORA2AADORA1 | |
| SCHEMBL2547711 | 0.69 | METAP2 (0.41) | PIK3CDALDH1A1 | |
| SCHEMBL2547707 | 0.69 | METAP2 (0.41) | PIK3CDALDH1A1 | |
| SCHEMBL2544609 | 0.67 | METAP2 (0.43) | PIK3CDPDE10AADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | PIK3CD 4573/4885PDE10A 4789/4885ALDH1A1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.